Non‐adherence to interferon‐beta therapy in Swedish patients with multiple sclerosis

Cunningham A, Gottberg K, von Koch L, Hillert J. Non‐adherence to interferon‐beta therapy in Swedish patients with multiple sclerosis. 
Acta Neurol Scand: 2010: 121: 154–160.
© 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard.

[1]  A. Sominanda.  Interferon-beta treatment in multiple sclerosis : Analysis of neutralizing antibodies , 2008 .

[2]  L. von Koch,et al.  Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: A population-based study , 2008, Multiple sclerosis.

[3]  T. Dwyer,et al.  Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses , 2008, Pharmacoepidemiology and drug safety.

[4]  S. Sorbi,et al.  Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis , 2007, European Neurology.

[5]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[6]  A. Noronha,et al.  Guidelines on use of anti‐IFN‐B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐B antibodies in multiple sclerosis , 2007, European journal of neurology.

[7]  D. Cox,et al.  Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. , 2006, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[8]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[9]  R. Holsinger,et al.  Left insular stroke is associated with adverse cardiac outcome , 2006, Neurology.

[10]  C. Pozzilli,et al.  Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis , 2005, European journal of neurology.

[11]  J. Haas,et al.  Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®) , 2005, European journal of neurology.

[12]  X. Montalban,et al.  Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis , 2005, Multiple sclerosis.

[13]  J. S. Butler,et al.  Factors leading patients to discontinue multiple sclerosis therapies. , 2005, Journal of the American Pharmacists Association : JAPhA.

[14]  M Hutchinson,et al.  Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns , 2005, Multiple sclerosis.

[15]  A. Langer-Gould,et al.  Strategies for managing the side effects of treatments for multiple sclerosis , 2004, Neurology.

[16]  J. Poirier,et al.  Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. , 2004, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[17]  M. Attanasio,et al.  Long-term interferon-β treatment for multiple sclerosis , 2003, Neurological Sciences.

[18]  H. Tremlett,et al.  Interrupted therapy , 2003, Neurology.

[19]  E. Keenan,et al.  Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre , 2003, Journal of neurology, neurosurgery, and psychiatry.

[20]  T. Vollmer,et al.  Predictors of Adherence to Glatiramer Acetate Therapy in Individuals with Self‐Reported Progressive Forms of Multiple Sclerosis* , 2003, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[21]  L. Munari,et al.  Interferon in relapsing-remitting multiple sclerosis. , 2001, The Cochrane database of systematic reviews.

[22]  M. Namey,et al.  Adherence to disease-modifying therapy in multiple sclerosis: Part II. , 2001, Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses.

[23]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[24]  A N N Gardulf,et al.  Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects , 2000, Multiple sclerosis.

[25]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[26]  D. Goodkin,et al.  Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis , 1999, Multiple sclerosis.

[27]  D. Goodkin,et al.  Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la , 1998, Multiple sclerosis.

[28]  D. Mohr,et al.  Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment , 1996, Multiple sclerosis.

[29]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[30]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[31]  D. Goodin.  Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. , 2006, Journal of neurology.

[32]  Andrew Russell,et al.  Innovative ways of responding to the information needs of people with MS. , 2005, British journal of nursing.

[33]  M. Attanasio,et al.  Long-term interferon-beta treatment for multiple sclerosis. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[34]  D. Goodkin,et al.  Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject , 2001, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[35]  M. Namey,et al.  Adherence to disease-modifying therapy in multiple sclerosis: Part I. , 2001, Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses.